(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Agile Therapeutics, A-Mark Precious Metals, and iRobot.

The three biggest losers today are Acorda Therapeutics, Agenus, and USD Partners LP.

Winners today

1. Agile Therapeutics (AGRX) – 23.81%

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

NASDAQ ended the session with Agile Therapeutics rising 23.81% to $0.36 on Monday while NASDAQ jumped 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Agile Therapeutics has a trailing twelve months EPS of $7.31.

PE Ratio

Agile Therapeutics has a trailing twelve months price to earnings ratio of 0.05. Meaning, the purchaser of the share is investing $0.05 for every dollar of annual earnings.

Sales Growth

Agile Therapeutics’s sales growth is 10.3% for the present quarter and 2.3% for the next.

More news about Agile Therapeutics.

2. A-Mark Precious Metals (AMRK) – 19.34%

A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company. It operates in three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers various ancillary services, including financing, storage, consignment, logistics, and various customized financial programs; and designs and produces minted silver products. The Direct-to-Consumer segment provides access to an array of gold, silver, copper, platinum, and palladium products through its websites and marketplaces. It operates five company-owned websites targeting specific niches within the precious metals retail market. This segment also operates as a direct retailer of precious metals to the investor community and markets its precious metal products on television, radio, and the internet, as well as through customer service outreach. The Secured Lending segment originates and acquires commercial loans secured by bullion and numismatic coins; and serves coin and precious metal dealers, investors, and collectors. It serves customers, including financial institutions, bullion retailers, industrial manufacturers and fabricators, sovereign mints, refiners, coin and metal dealers, investors, collectors, and e-commerce and other retail customers. The company has operations in the United States, rest of North America, Europe, the Asia Pacific, Africa, and Australia. A-Mark Precious Metals, Inc. was founded in 1965 and is headquartered in El Segundo, California.

NASDAQ ended the session with A-Mark Precious Metals jumping 19.34% to $39.05 on Monday, following the last session’s upward trend. NASDAQ rose 0.03% to $16,253.96, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, A-Mark Precious Metals has a trailing twelve months EPS of $4.5.

PE Ratio

A-Mark Precious Metals has a trailing twelve months price to earnings ratio of 8.68. Meaning, the purchaser of the share is investing $8.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.71%.

More news about A-Mark Precious Metals.

3. iRobot (IRBT) – 12.67%

iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides Root robots for coding, discovery, and play; Roomba Combo mopping and vacuuming robot; and accessories, including robot vacuum and mop, handheld vacuum, and air purifier, educational coding robot, and accessory bundles. The company sells its products through chain stores and other national retailers, value- added distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.

NASDAQ ended the session with iRobot jumping 12.67% to $9.96 on Monday while NASDAQ rose 0.03% to $16,253.96.

Earnings Per Share

As for profitability, iRobot has a trailing twelve months EPS of $-11.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4%.

Moving Average

iRobot’s worth is way under its 50-day moving average of $19.53 and way under its 200-day moving average of $33.71.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, iRobot’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 14.1%, now sitting on 1.56B for the twelve trailing months.

More news about iRobot.

4. VerifyMe (VRME) – 10%

VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.

NASDAQ ended the session with VerifyMe jumping 10% to $1.65 on Monday, following the last session’s downward trend. NASDAQ rose 0.03% to $16,253.96, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-0.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.16%.

Yearly Top and Bottom Value

VerifyMe’s stock is valued at $1.65 at 17:32 EST, way below its 52-week high of $2.27 and way higher than its 52-week low of $0.85.

Sales Growth

VerifyMe’s sales growth is negative 7.8% for the ongoing quarter and 1% for the next.

More news about VerifyMe.

5. Fastly (FSLY) – 7.74%

Fastly, Inc. operates an edge cloud platform for processing, serving, and securing its customer's applications in the United States, the Asia Pacific, Europe, and internationally. The edge cloud is a category of Infrastructure as a Service that enables developers to build, secure, and deliver digital experiences at the edge of the internet. The company offers network services to speed up and optimize the delivery of web and application traffic; device detection and geolocation; content delivery network, such as dynamic site acceleration, origin shield, instant purge, surrogate keys, programmatic control, content compression, reliability features, fanout, domainr, privacy, and modern protocols and performance services; and video/ streaming solutions and services, including live streaming, video on demand, and media shield. It also provides security solutions, such as DDoS protection, next-gen WAF, bot management, API and ATO protection, advanced rate limiting, and compliance services; load balancing; image optimization; transport layer security (TLS), platform TLS, and certainly; and origin connect. It serves customers operating in digital publishing, media and entertainment, technology, online education, travel and hospitality, and financial services industries. The company was formerly known as SkyCache, Inc. and changed its name to Fastly, Inc. in May 2012. Fastly, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.

NYSE ended the session with Fastly rising 7.74% to $13.50 on Monday, after five sequential sessions in a row of losses. NYSE jumped 0.18% to $18,154.37, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Fastly has a trailing twelve months EPS of $-1.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.16%.

Volatility

Fastly’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.33%, a negative 0.57%, and a positive 3.26%.

Fastly’s highest amplitude of average volatility was 1.33% (last week), 1.61% (last month), and 3.26% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Fastly’s EBITDA is -75.33.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 75% and 66.7%, respectively.

More news about Fastly.

6. Rock (RKT) – 6.87%

Rocket Companies, Inc., a fintech holding company, provides mortgage lending, title and settlement services, and other financial technology services in the United States and Canada. It operates through two segments, Direct to Consumer and Partner Network. The company's solutions include Rocket Mortgage, a mortgage lender; Amrock that provides title insurance, property valuation, and settlement services; Rocket Homes, a home search platform and real estate agent referral network, which offers technology-enabled services to support the home buying and selling experience; and Rocket Loans, an online-based personal loans business. It also offers Core Digital Media, a online marketing platform in the mortgage and personal financial product sectors; Rocket Money, a personal finance app that helps clients manage every aspect of their financial lives; Lendesk, a software services company that provides a point of sale system for mortgage professionals and a loan origination system for private lenders; Rock Connections, a sales and support platform specializing in contact center services; and Rocket Innovation Studio that recruits and mentors top technology talent. In addition, the company originates, closes, sells, and services agency-conforming loans. Rocket Companies, Inc. was founded in 1985 and is headquartered in Detroit, Michigan. The company operates as a subsidiary of Rock Holdings Inc.

NYSE ended the session with Rock rising 6.87% to $13.84 on Monday, after two successive sessions in a row of losses. NYSE rose 0.18% to $18,154.37, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Rock has a trailing twelve months EPS of $1.8.

PE Ratio

Rock has a trailing twelve months price to earnings ratio of 7.68. Meaning, the purchaser of the share is investing $7.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.65%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 133.3% and 500%, respectively.

Yearly Top and Bottom Value

Rock’s stock is valued at $13.84 at 17:32 EST, below its 52-week high of $15.19 and way higher than its 52-week low of $7.17.

More news about Rock.

7. Coinbase (COIN) – 6.68%

Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy in the United States and internationally. The company offers the primary financial account in the crypto economy for consumers; and a marketplace with a pool of liquidity for transacting in crypto assets for institutions. It also provides technology and services that enable developers to build crypto products and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase rising 6.68% to $256.99 on Monday, after four consecutive sessions in a row of losses. NASDAQ jumped 0.03% to $16,253.96, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $0.36.

PE Ratio

Coinbase has a trailing twelve months price to earnings ratio of 713.86. Meaning, the purchaser of the share is investing $713.86 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.74%.

More news about Coinbase.

8. Albemarle (ALB) – 6.67%

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

NYSE ended the session with Albemarle rising 6.67% to $131.69 on Monday while NYSE rose 0.18% to $18,154.37.

Earnings Per Share

As for profitability, Albemarle has a trailing twelve months EPS of $13.36.

PE Ratio

Albemarle has a trailing twelve months price to earnings ratio of 9.86. Meaning, the purchaser of the share is investing $9.86 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.71%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Albemarle’s EBITDA is 1.8.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 97.6% and a negative 93.6%, respectively.

More news about Albemarle.

9. Aptose Biosciences (APTO) – 6.52%

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

NASDAQ ended the session with Aptose Biosciences jumping 6.52% to $1.47 on Monday while NASDAQ jumped 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Aptose Biosciences has a trailing twelve months EPS of $-7.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -225%.

Volume

Today’s last reported volume for Aptose Biosciences is 113170 which is 17.98% above its average volume of 95919.

More news about Aptose Biosciences.

10. VALE (VALE) – 5.97%

Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally. The company operates through Iron Solutions and Energy Transition Materials segments. The Iron Solutions segment produces and extracts iron ore and pellets, manganese, and other ferrous products; and provides related logistic services. The Energy Transition Materials segment produces and extracts nickel used to produce stainless steel, electric vehicles, and metal alloys; and its by-products, such as gold, silver, cobalt, precious metals, platinum, and others, as well as copper used in the construction sector to produce pipes and electrical wires. The company was formerly known as Companhia Vale do Rio Doce and changed its name to Vale S.A. in May 2009. Vale S.A. was founded in 1942 and is headquartered in Rio de Janeiro, Brazil.

NYSE ended the session with VALE rising 5.97% to $12.51 on Monday while NYSE rose 0.18% to $18,154.37.

Earnings Per Share

As for profitability, VALE has a trailing twelve months EPS of $1.83.

PE Ratio

VALE has a trailing twelve months price to earnings ratio of 6.83. Meaning, the purchaser of the share is investing $6.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.98%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 7.3% and 39%, respectively.

More news about VALE.

Losers Today

1. Acorda Therapeutics (ACOR) – -19.64%

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

NASDAQ ended the session with Acorda Therapeutics falling 19.64% to $1.35 on Monday while NASDAQ jumped 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Acorda Therapeutics has a trailing twelve months EPS of $2.61.

PE Ratio

Acorda Therapeutics has a trailing twelve months price to earnings ratio of 0.52. Meaning, the purchaser of the share is investing $0.52 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.68%.

Yearly Top and Bottom Value

Acorda Therapeutics’s stock is valued at $1.35 at 17:32 EST, way under its 52-week high of $24.20 and higher than its 52-week low of $1.31.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Acorda Therapeutics’s EBITDA is -0.72.

More news about Acorda Therapeutics.

2. Agenus (AGEN) – -16.62%

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

NASDAQ ended the session with Agenus sliding 16.62% to $0.42 on Monday while NASDAQ rose 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Agenus has a trailing twelve months EPS of $-0.69.

Volume

Today’s last reported volume for Agenus is 12236600 which is 16.94% above its average volume of 10463900.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 31.8% and 60%, respectively.

More news about Agenus.

3. USD Partners LP (USDP) – -15.97%

USD Partners LP acquires, develops, and operates midstream infrastructure assets and logistics solutions for crude oil, biofuels, and other energy-related products in the United States and Canada. It operates through two segments, Terminalling Services and Fleet Services. The Terminalling Services segment owns and operates Hardisty terminal, an origination terminal for loading various grades of Canadian crude oil onto railcars for transportation to end markets; Stroud terminal, a crude oil destination terminal, which is used to facilitate rail-to-pipeline shipments of crude oil located in Stroud, Oklahoma; Casper terminal, a crude oil storage, blending, and railcar loading terminal located in Casper, Wyoming; and West Colton Terminal, an unit train-capable destination terminals that trans load approximately 13,000 barrels per day ethanol and renewable diesel received by rail from producers onto trucks. The Fleet Services segment provides leased railcars and fleet services related to the transportation of liquid hydrocarbons. It operates a fleet of 200 railcars. USD Partners GP LLC serves as the general partner of the company. The company was incorporated in 2014 and is headquartered in Houston, Texas.

NYSE ended the session with USD Partners LP sliding 15.97% to $0.11 on Monday while NYSE jumped 0.18% to $18,154.37.

Earnings Per Share

As for profitability, USD Partners LP has a trailing twelve months EPS of $0.03.

PE Ratio

USD Partners LP has a trailing twelve months price to earnings ratio of 3.75. Meaning, the purchaser of the share is investing $3.75 for every dollar of annual earnings.

More news about USD Partners LP.

4. Identiv (INVE) – -7.01%

Identiv, Inc., a security technology company, that provides secure identification and physical security solutions that secure things, data, and physical places worldwide. It operates in two segments, Identity and Premises. The Identity segment offers products and solutions that enables secure access to information serving the logical access and cyber security markets, as well as protecting connected objects and information using radio-frequency identification embedded security. The Premises segment provides solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, and apartment buildings. The company sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.

NASDAQ ended the session with Identiv dropping 7.01% to $5.17 on Monday, after three successive sessions in a row of losses. NASDAQ rose 0.03% to $16,253.96, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Identiv has a trailing twelve months EPS of $-0.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.77%.

More news about Identiv.

5. Aldeyra Therapeutics (ALDX) – -6.78%

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

NASDAQ ended the session with Aldeyra Therapeutics sliding 6.78% to $4.40 on Monday, after four sequential sessions in a row of gains. NASDAQ jumped 0.03% to $16,253.96, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Aldeyra Therapeutics has a trailing twelve months EPS of $-0.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.73%.

Yearly Top and Bottom Value

Aldeyra Therapeutics’s stock is valued at $4.40 at 17:32 EST, way below its 52-week high of $11.97 and way above its 52-week low of $1.42.

More news about Aldeyra Therapeutics.

6. Niu Technologies (NIU) – -6.25%

Niu Technologies designs, manufactures, and sells smart electric scooters in the People's Republic of China. The company offers RQi, NQi, MQi, SQi, UQi, and Gova series electric scooters and motorcycles; KQi series one kick-scooters; BQi series e-bikes; and Niu Aero Sports Bicycles. It also provides accessories and spare parts under the NIU brand name comprising scooter accessories, such as raincoats, gloves, knee pads, storage baskets and tail boxes, smart phone holders, backrests, and locks; lifestyle accessories, which includes T-shirts, coats, sweaters and hoodies, jeans, hats, bags, jewelry, notebook, badges, key chain, and mugs; and performance upgrade components that comprises of upgraded wheels, shock absorbers, brake calipers, and carbon fiber body panels. In addition, the company, through its NIU app, offers online repair request, DIY repairs, service station locator, theft reporting, smart check, and smart services, as well as NIU cover, which provides insurance services. Niu Technologies sells and services its products through city partners and franchised stores, distributors, and third-party e-commerce platforms and the company's online store. The company was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Niu Technologies falling 6.25% to $1.80 on Monday while NASDAQ jumped 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Niu Technologies has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Volatility

Niu Technologies’s last week, last month’s, and last quarter’s current intraday variation average was 1.28%, 0.39%, and 3.49%.

Niu Technologies’s highest amplitude of average volatility was 7.26% (last week), 4.25% (last month), and 3.49% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Niu Technologies’s stock is considered to be oversold (<=20).

Moving Average

Niu Technologies’s value is below its 50-day moving average of $1.91 and way under its 200-day moving average of $2.86.

Revenue Growth

Year-on-year quarterly revenue growth declined by 19.6%, now sitting on 2.79B for the twelve trailing months.

More news about Niu Technologies.

7. AngioDynamics (ANGO) – -5.97%

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

NASDAQ ended the session with AngioDynamics dropping 5.97% to $6.61 on Monday while NASDAQ rose 0.03% to $16,253.96.

Earnings Per Share

As for profitability, AngioDynamics has a trailing twelve months EPS of $-0.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.49%.

Yearly Top and Bottom Value

AngioDynamics’s stock is valued at $6.61 at 17:32 EST, way under its 52-week high of $11.38 and way above its 52-week low of $5.26.

More news about AngioDynamics.

8. USA Compression Partners, LP (USAC) – -5.02%

USA Compression Partners, LP provides natural gas compression services. The company offers compression services to oil companies and independent producers, processors, gatherers, and transporters of natural gas and crude oil, as well as operates stations. It primarily focuses on providing natural gas compression services to infrastructure applications, including centralized natural gas gathering systems and processing facilities, as well as gas lift applications for crude oil wells. As of December 31, 2022, the company had 3,716,854 horsepower in its fleet. USA Compression Partners, LP was founded in 1998 and is headquartered in Austin, Texas.

NYSE ended the session with USA Compression Partners, LP falling 5.02% to $26.48 on Monday, after two consecutive sessions in a row of losses. NYSE rose 0.18% to $18,154.37, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, USA Compression Partners, LP has a trailing twelve months EPS of $0.2.

PE Ratio

USA Compression Partners, LP has a trailing twelve months price to earnings ratio of 132.4. Meaning, the purchaser of the share is investing $132.4 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.1%.

Volume

Today’s last reported volume for USA Compression Partners, LP is 400495 which is 7.46% below its average volume of 432785.

More news about USA Compression Partners, LP.

9. Affimed N.V. (AFMD) – -4.32%

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

NASDAQ ended the session with Affimed N.V. falling 4.32% to $6.20 on Monday while NASDAQ jumped 0.03% to $16,253.96.

Earnings Per Share

As for profitability, Affimed N.V. has a trailing twelve months EPS of $-8.56.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.55%.

More news about Affimed N.V..

10. Dell (DELL) – -4.17%

Dell Technologies Inc. designs, develops, manufactures, markets, sells, and supports various comprehensive and integrated solutions, products, and services in the Americas, Europe, the Middle East, Asia, and internationally. The company operates through two segments, Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment provides modern and traditional storage solutions, including all-flash arrays, scale-out file, object platforms, hyper-converged infrastructure, and software-defined storage; and general-purpose and AI-optimized servers. This segment also offers networking products and services comprising wide area network infrastructure, data center and edge networking switches, and cables and optics that help its business customers to transform and modernize their infrastructure, mobilize and enrich end-user experiences, and accelerate business applications and processes; software and peripherals; and consulting, support, and deployment services. The CSG segment provides desktops, workstations, and notebooks; displays, docking stations, keyboards, mice, webcam, and audio devices; and third-party software and peripherals, as well as configuration, support and deployment, and extended warranty services. It is involved in cybersecurity technology-driven security solutions to prevent security breaches, detect malicious activity, respond rapidly when a security breach occurs, and identify emerging threats; originating, collecting, and servicing customer financing arrangements; and the resale of VMware products and services. The company serves enterprises, public institutions, and small and medium-sized businesses through its direct sales channel, value-added resellers, system integrators, distributors, and retailers. The company was formerly known as Denali Holding Inc. and changed its name to Dell Technologies Inc. in August 2016. Dell Technologies Inc. was founded in 1984 and is headquartered in Round Rock, Texas.

NYSE ended the session with Dell dropping 4.17% to $127.18 on Monday, after two sequential sessions in a row of gains. NYSE rose 0.18% to $18,154.37, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Dell has a trailing twelve months EPS of $4.36.

PE Ratio

Dell has a trailing twelve months price to earnings ratio of 29.17. Meaning, the purchaser of the share is investing $29.17 for every dollar of annual earnings.

Volatility

Dell’s last week, last month’s, and last quarter’s current intraday variation average was 2.14%, 0.52%, and 2.67%.

Dell’s highest amplitude of average volatility was 3.56% (last week), 2.26% (last month), and 2.67% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 3.9% and positive 9.9% for the next.

More news about Dell.

Stay up to date with our winners and losers daily report